Live Analyst Rating Changes 24955 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Michael Ryskin
BofA

Michael Ryskin

Wall Street Analyst
★★★★☆
#540
on 13Foresight · ranked by our own returns
67%
Success Rate
+8.6%
Average Return
60 of 89 calls profitable · +4.0% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 67% of Michael Ryskin's ratings turned a profit when each position was held for 2 year — averaging +8.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

120 Buy 70 Hold 42 Sell
Michael's Stock Coverage 38 ratings · 2026-08-15
Company Date Position Consensus Price Target 2-Yr Return vs S&P 500
IDXX
Idexx Laboratories
Aug 14, 2026 HOLD Buy
+29.9% avg upside
17 analysts
$665.00
20.69% Upside
· ·
ELAN
Elanco Animal Health
Aug 12, 2026 BUY Strong Buy
+34.8% avg upside
18 analysts
$34.00
43.56% Upside
+7.0% ·
ALMR
Alamar Biosciences, Inc.
Aug 10, 2026 HOLD Strong Buy
+0.7% avg upside
5 analysts
$31.00
6.60% Downside
· ·
TXG
10x Genomics
Aug 07, 2026 HOLD Buy
-26.6% avg upside
18 analysts
+7.8% ·
SDGR
Schrodinger
Aug 06, 2026 BUY Strong Buy
+55.8% avg upside
15 analysts
-1.2% ·
CAI
Caris Life Sciences, Inc.
Aug 06, 2026 BUY Strong Buy
+27.2% avg upside
20 analysts
+9.0% ·
BRKR
Bruker
Aug 05, 2026 BUY Buy
-1.4% avg upside
22 analysts
+10.0% ·
STVN
Stevanato Group
Aug 05, 2026 BUY Strong Buy
+29.8% avg upside
13 analysts
+4.8% ·
ILMN
Illumina
Aug 05, 2026 SELL Buy
-8.2% avg upside
31 analysts
$140.00
26.64% Downside
+4.5% ·
WAT
Waters
Aug 04, 2026 HOLD Strong Buy
-4.5% avg upside
31 analysts
$415.00
0.76% Upside
+4.4% ·
MYGN
Myriad Genetics
Aug 03, 2026 SELL Hold
+487.2% avg upside
24 analysts
$3.20
5.60% Upside
-7.0% ·
TEM
Tempus AI, Inc. Class A
Aug 03, 2026 HOLD Buy
+24.1% avg upside
21 analysts
$52.00
0.27% Downside
+13.1% ·
DHR
Danaher
Aug 03, 2026 BUY Strong Buy
+3.9% avg upside
45 analysts
$230.00
13.55% Upside
+3.6% ·
GH
Guardant Health
Jul 31, 2026 BUY Strong Buy
+3.9% avg upside
31 analysts
-2.9% ·
MTD
Mettler-Toledo
Jul 31, 2026 BUY Buy
-14.5% avg upside
18 analysts
+1.6% ·
ALGN
Align Tech
Jul 30, 2026 SELL Strong Buy
+64.1% avg upside
21 analysts
-4.6% ·
ICLR
Icon
Jul 30, 2026 SELL Strong Buy
+15.1% avg upside
26 analysts
$160.00
1.87% Downside
+1.4% ·
LH
Labcorp Holdings
Jul 30, 2026 BUY Strong Buy
-14.9% avg upside
37 analysts
$360.00
13.07% Upside
+2.2% ·
FTRE
Fortrea Holdings Inc.
Jul 30, 2026 SELL Buy
+20.9% avg upside
12 analysts
+8.8% ·
PAHC
Phibro Animal Health
Jul 28, 2026 SELL Sell
+8.0% avg upside
10 analysts
+5.5% ·
IQV
IQVIA Holdings
Jul 28, 2026 BUY Strong Buy
+3.3% avg upside
39 analysts
$280.00
18.37% Upside
-2.6% ·
ZTS
Zoetis
Jul 28, 2026 HOLD Buy
+61.0% avg upside
23 analysts
-4.8% ·
WST
West Pharmaceutical Services
Jul 24, 2026 BUY Strong Buy
+5.0% avg upside
18 analysts
$410.00
17.42% Upside
+5.5% ·
DGX
Quest Diagnostics
Jul 24, 2026 BUY Buy
-21.8% avg upside
34 analysts
$265.00
12.99% Upside
+4.3% ·
TMO
Thermo Fisher
Jul 23, 2026 BUY Strong Buy
+2.4% avg upside
38 analysts
$650.00
10.46% Upside
+2.8% ·
EVO
Evotec AG
Jul 15, 2026 SELL Buy
+327.8% avg upside
9 analysts
$2.40
22.52% Upside
+2.5% ·
NEO
NeoGenomics
Jul 13, 2026 HOLD Strong Buy
+7.2% avg upside
18 analysts
$16.00
0.41% Upside
+13.0% ·
CRL
Charles River Labs
Jun 05, 2026 BUY Strong Buy
-15.9% avg upside
35 analysts
+54.4% ·
A
Agilent
Jun 02, 2026 BUY Strong Buy
+0.3% avg upside
33 analysts
$155.00
4.37% Upside
+10.2% ·
RVTY
Revvity
May 14, 2026 HOLD Buy
-7.4% avg upside
23 analysts
+22.4% ·
QGEN
Qiagen
May 13, 2026 BUY Buy
-0.0% avg upside
24 analysts
$49.00
14.00% Upside
+32.5% ·
AVTR
Avantor
Feb 11, 2026 HOLD Buy
+13.0% avg upside
26 analysts
$11.00
19.55% Downside
+41.7% ·
MRVI
Maravai Lifesciences Holdings
Mar 03, 2025 BUY Strong Buy
+152.8% avg upside
17 analysts
$8.00
40.33% Upside
+88.7% ·
CERT
Certara
Feb 27, 2025 BUY Buy
+63.8% avg upside
22 analysts
$17.00
112.43% Upside
-35.5% ·
DNA
Ginkgo Bioworks Holdings
Jul 18, 2024 SELL Strong Sell
+3.2% avg upside
6 analysts
$10.00
47.36% Upside
+34.7% ·
SDCCQ
SmileDirectClub
Aug 08, 2023 SELL Sell
+5139900.0% avg upside
10 analysts
$0.40
399900.07% Upside
· ·
ABSI
AbSci
Apr 24, 2023 SELL Strong Buy
+31.5% avg upside
18 analysts
$2.40
73.84% Downside
-107.7% ·
RXRX
Recursion Pharmaceuticals
Apr 18, 2022 HOLD Buy
+149.1% avg upside
12 analysts
$10.00
216.41% Upside
+13.3% ·
🔒 33 more ratings — with price targets, crowd consensus and our measured returns.
Free account unlocks every analyst's full coverage table.
Michael Ryskin — Frequently Asked Questions
How accurate are Michael Ryskin's stock ratings?
Based on the calls 13Foresight could measure, about 66% of Michael's ratings were profitable over a one-year hold, with an average return of +6.2% per rating, or +2.5% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Michael ranked on 13Foresight?
Michael Ryskin is currently ranked #540 with a 4-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Michael cover?
Michael most recently has ratings on IDXX, ELAN, ALMR, TXG, SDGR, CAI, BRKR, STVN, ILMN, WAT, MYGN, TEM and 26 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.